B
Bethan Psaila
Researcher at University of Oxford
Publications - 96
Citations - 6476
Bethan Psaila is an academic researcher from University of Oxford. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 27, co-authored 68 publications receiving 5288 citations. Previous affiliations of Bethan Psaila include Memorial Sloan Kettering Cancer Center & Cornell University.
Papers
More filters
Journal ArticleDOI
The metastatic niche: adapting the foreign soil
TL;DR: Emerging data that support the 'seed and soil' hypothesis for metastasis are presented and the potential mechanism and temporal sequence by which changes occur in tissues distant from the primary tumour are outlined.
Journal ArticleDOI
Pre-metastatic niches: organ-specific homes for metastases
Héctor Peinado,Haiying Zhang,Irina Matei,Bruno Costa-Silva,Ayuko Hoshino,Gonçalo Rodrigues,Gonçalo Rodrigues,Bethan Psaila,Rosandra N. Kaplan,Jacqueline Bromberg,Yibin Kang,Mina J. Bissell,Thomas R. Cox,Amato J. Giaccia,Janine T. Erler,Sachie Hiratsuka,Cyrus M. Ghajar,David Lyden,David Lyden +18 more
TL;DR: This Review summarizes the main processes and new mechanisms involved in the formation of the pre-metastatic niche and describes the main mechanisms used to modify organs of future metastasis.
Journal ArticleDOI
Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
James B. Bussel,Gregory Cheng,Mansoor N. Saleh,Bethan Psaila,Lidia Kovaleva,Balkis Meddeb,Janusz Kloczko,Habib Hassani,Bhabita Mayer,Nicole L. Stone,Michael Arning,Drew Provan,Julian Jenkins +12 more
TL;DR: Eltrombopag increased platelet counts in a dose-dependent manner in patients with relapsed or refractory ITP, and Bleeding also decreased during treatment in these two groups.
Journal ArticleDOI
Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
James B. Bussel,Drew Provan,Tahir Shamsi,Gregory Cheng,Bethan Psaila,Bethan Psaila,Lidia Kovaleva,Abdulgabar Salama,Julian Jenkins,Debasish F. Roychowdhury,Bhabita Mayer,Nicole L. Stone,Michael Arning +12 more
TL;DR: Eltrombopag is an effective treatment for managment of thrombocytopenia in chronic ITP and a dose increase to 75 mg is explored, and platelet counts generally returned to baseline values within 2 weeks after the end of treatment.
Journal ArticleDOI
Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond
TL;DR: The inextricable relationship between bone stromal components, metastasizing cells, and bone marrow-derived hematopoietic cells and their roles in carcinogenesis and metastasis is discussed.